Summary from GEO: "KRAS is one of the driver oncogenes in non-small cell lung cancer (NSCLC), but remains refractory to current modalities of targeted pathway inhibition, which include inhibiting downstream kinase MEK to circumvent KRAS activation. Here, we show that pulsatile, rather than continuous, treatment with MEK inhibitors (MEKis) maintains T cell activation and better control tumor growth...

Summary from GEO: "Here we demonstrate the differential gene expression of two breast cancer cell lines treated with PI3K and PDK1 inhibitors." Overall design from GEO: "Total RNA was isolated after 4h of treatment from breast cancer cell lines JIMT1 and HCC1954 from three biological replicates. Treatments were DMSO (0.1%), BYL719 (PI3K alpha inhibitor) 1 uM, GSK2334470 (PDK1 inhibitor) 1uM,...

From the dbGaP study description: "Outlier analyses represent a versatile method to identify predictive biomarkers of response to both targeted agents and chemotherapy. We performed whole genome sequencing (WGS) of tumor and germline blood from a patient with metastatic small cell carcinoma of the ureter who experienced a durable complete response to a combination of irinotecan plus AZD7762, a checkpoint...